Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
Oncogene|April 3, 2019
Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistanceGabriele D'Errico, Marta Alonso-Nocelo, Mireia Vallespinos, et al.
Journal of the National Cancer Institute|October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Journal of Nanobiotechnology|December 24, 2024
Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasisAdrián Palencia-Campos, Laura Ruiz-Cañas, Marcelina Abal-Sanisidro, et al.
Bioorganic & Medicinal Chemistry Letters|September 29, 2014
Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazinesJavier de Vicente, Remy Lemoine, Mark Bartlett, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Metal impurities cause false positives in high-throughput screening campaignsJohannes C Hermann, Yingsi Chen, Charles Wartchow, et al.
Stem Cell Research|September 16, 2016
Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemnessLukas Perkhofer, Karolin Walter, Ivan G Costa, et al.
Cell Stem Cell|November 8, 2011
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapyEnza Lonardo, Patrick C Hermann, Maria-Theresa Mueller, et al.
JAACAP Open|June 1, 2026
Social Media Usage and Its Association With the Social Media Addiction Questionnaire Scale Among Early AdolescentsJacob C Hermann, Kevin M Cummins, Shana Adise, et al.
United European Gastroenterology Journal|March 28, 2020
Pancreatic cancer-derived organoids - a disease modeling tool to predict drug responsePierre-Olivier Frappart, Karolin Walter, Johann Gout, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Mark A Socinski, Edward B Garon, et al.
Pageof 22